Surface modification of doxorubicin-loaded nanoparticles based on polydopamine with pH-sensitive property for tumor targeting therapy.
Surface modification of doxorubicin-loaded nanoparticles based on polydopamine with pH-sensitive property for tumor targeting therapy.
复制标题
DOI：
10.1080/10717544.2018.1440447
复制
发表时间：
2018-11
期刊：
影响因子：
6
通讯作者：
Han M
中科院分区：
文献类型：
--
作者：
Bi D;Zhao L;Yu R;Li H;Guo Y;Wang X;Han M
目前纳米颗粒表面修饰的一个主要挑战是需要化学反应性聚合物层，这种修饰通常是复杂的，低效的，并且可能导致聚合物失去包封药物的能力。为了克服这一限制，我们采用了一种ph敏感平台，使用聚多巴胺（PDA）作为纳米颗粒（NPs）表面功能化的一种方式。该方法只需要在多巴胺弱碱性溶液中短暂孵育，操作简单，适用于多种聚合物载体，无论其化学反应性如何。我们成功地将阿霉素(DOX)- pda -聚乳酸-羟基乙酸（PLGA） NPs与两种典型的表面改性剂：叶酸（FA）和肽（Arg-Gly-Asp， RGD）偶联。DOX-PDA-FA-NPs和DOX-PDA-RGD-NPs（靶向纳米颗粒）通过粒径、zeta电位和表面形貌进行表征。它们在各种生理溶液中都很稳定，在药物释放中表现出ph敏感性。与DOX-NPs相比，靶向纳米颗粒对HeLa细胞具有良好的靶向能力。此外，体内研究表明，靶向纳米颗粒的肿瘤抑制率超过70%，同时显著降低了DOX的副作用，改善了药物在肿瘤中的分布。我们的研究表明，由PDA和各种功能配体修饰的DOX-PLGA-NPs是一种很有前景的靶向肿瘤治疗纳米载体。
One major challenge of current surface modification of nanoparticles is the demand for chemical reactive polymeric layers, such modification is always complicated, inefficient, and may lead the polymer lose the ability to encapsulate drug. To overcome this limitation, we adopted a pH-sensitive platform using polydopamine (PDA) as a way of functionalizing nanoparticles (NPs) surfaces. All this method needed to be just a brief incubation in weak alkaline solution of dopamine, which was simple and applicable to a variety of polymer carriers regardless of their chemical reactivity. We successfully conjugated the doxorubicin (DOX)-PDA-poly (lactic-co-glycolic acid) (PLGA) NPs with two typical surface modifiers: folate (FA) and a peptide (Arg-Gly-Asp, RGD). The DOX-PDA-FA-NPs and DOX-PDA-RGD-NPs (targeting nanoparticles) were characterized by particle size, zeta potential, and surface morphology. They were quite stable in various physiological solutions and exhibited pH-sensitive property in drug release. Compared to DOX-NPs, the targeting nanoparticles possessed an excellent targeting ability against HeLa cells. In addition, the in vivo study demonstrated that targeting nanoparticles achieved a tumor inhibition rate over 70%, meanwhile prominently decreased the side effects of DOX and improve drug distribution in tumors. Our studies indicated that the DOX-PLGA-NPs modified with PDA and various functional ligands are promising nanocarriers for targeting tumor therapy.
登录
查看更多内容
影响因子：
5.8
作者：
Hong, Jingyi;Li, Yanhong;Wang, Xiangtao
通讯作者：
Wang, Xiangtao
影响因子：
10.8
作者：
Amin, Mohamadreza;Mansourian, Mercedeh;ten Hagen, Timo L. M.
通讯作者：
ten Hagen, Timo L. M.
DOI：
10.1016/j.msec.2017.03.027
发表时间：
2017-07-01
影响因子：
7.9
作者：
Ai, Jin-wei;Liu, Bin;Liu, Wei-dong
通讯作者：
Liu, Wei-dong
影响因子：
3.4
作者：
Fan, Hailong;Yu, Xiang;Jin, Zhaoxia
通讯作者：
Jin, Zhaoxia
影响因子：
56.9
作者：
Lee, Haeshin;Dellatore, Shara M.;Messersmith, Phillip B.
通讯作者：
Messersmith, Phillip B.